Chikungunya Fever: The Roles of Integrative Medicine in the Post-vaccine Era

Chikungunya fever is becoming a major healthcare threat in more than 110 countries and may impact a total population of 2.8 billion, particularly those in East and Central Africa, South America, and Southeast Asia. 1,2VLA1553 (live-attenuated, single-dose, trade name IXCHIQ) and PXVX0317 (purified virus-like particles, trade name Vimkunya) are the two approved vaccines for Chikungunya virus (CHIKV). 3-6Their seroconversion rates were more than 95%, while their approval, accessibility, and indications differ across countries/regions. 5,6They thus will shift the paradigm